Qi Zhang
The University of Texas MD Anderson Cancer Center(US)
Publications by Year
Research Areas
Acute Myeloid Leukemia Research, Protein Degradation and Inhibitors, Multiple Myeloma Research and Treatments, Histone Deacetylase Inhibitors Research, Chronic Myeloid Leukemia Treatments
Most-Cited Works
- → A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity(2019)622 cited
- → Serine ADP-Ribosylation Depends on HPF1(2017)356 cited
- → Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials(2023)348 cited
- → Serine is a new target residue for endogenous ADP-ribosylation on histones(2016)243 cited
- → Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia(2022)173 cited
- → Overview of Research into mTOR Inhibitors(2022)147 cited
- → Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity,(2021)143 cited
- → Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models(2020)138 cited
- → Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia(2022)113 cited
- → Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models(2019)113 cited